Global T-Cell Therapy Market Size, Trends & Growth Opportunity, By Modality (Research, and Commercialized), By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), By Indication, By End User, By Region and Forecast from 2022-2027.
Global T-Cell Therapy Market
Global T-Cell Therapy Market was valued at USD 4.2 billion in 2021 which expected to reach USD 24.6 billion by 2027 at a CAGR 28.75%.
T-cells are a type of white blood cell that aid in the body's defence against infection and may even aid in the battle against cancer. It is also a component of the immune system. As a cutting-edge immunotherapy that aids in the treatment of various tumours, T-cell therapy is characterised. These modified cells are multiplied and then injected into the body to identify and eradicate cancer cells that have certain antigens on their surface.
Market Drivers
The global T-cell therapy market is anticipated to develop over the course of the forecast period due to the rise in cancer incidence and the rising number of patients who do not respond to alternative treatments. Additionally, it is projected that the rise in the number of adults and children contracting cancer would increase the need for an efficient and dependable therapeutic treatment technique to enhance the quality of patients' lives. For instance, according to data from Cancer Research UK, 14.1 million individuals worldwide were diagnosed with cancer in 2012.
Another important element propelling the expansion of the worldwide T-cell therapy market is the creation of fresh and efficient treatment choices to treat disease symptoms. For example, the U.S. Food and Drug Administration approved two CAR-T cell therapies in 2017 under the names Kymriah and Yescarta for the treatment of adult and pediatric lymphoblastic leukemia and advanced lymphoma, respectively. Over the course of the projection period, this is anticipated to fuel market expansion. The expansion of the worldwide T-cell therapy market is also being supported by the rise in government programmed for enhancing health systems and encouraging research for cell treatment in cancer.
Market Restraints
Cytokine release syndrome (CRS), as well as other neurological issues like seizures, coma, hallucinations, and delirium, may be brought on by T-cell treatment side effects. These are significant restraints that are anticipated to have a negative impact on the market for T-cell treatment globally throughout the projected period.
Market Segmentation
The Global T-Cell Therapy Market is segmented into Modality such as Research, and Commercialized. The research segment dominates the market with considerable market share in 2020, due to the high number of products in the clinical development phase. On the basis of therapy type, market is segmented into CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based. CAR T-cell therapy is fastest growing segment in the market. This is due to the exponential rise in the number of clinical trials for CAR-T therapies. On the basis of indication market is segmented into Hematologic Malignancies, Solid Tumors, and Others. Also, the market is segmented into end users such as Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes, and Others.
Impact of COVID-19
The COVID-19 pandemic has sparked a surge in funding for studies into how T-cell treatments can be used to treat viral infections. For instance, research released in December 2020 showed the therapy's potential to help high-risk COVID-19 patients. It is anticipated that this will lead to a rise in the use of T-cell therapies for viral infections.
Regional Analysis
The Global T-Cell Therapy Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The North American area dominates the global T-cell therapy industry in terms of revenue share. owing to the region's quick discovery and introduction of novel cancer medicines. For instance, according to data from the Centers for Disease Control and Prevention (CDC), around 171,000 people were diagnosed with blood cancer in the United States in 2016. Due to growing investment & significant research for the development of cancer therapeutics in the region, Europe is anticipated to be the second most important market in terms of revenue.
Key Players
Key Players operating in the global T-cell therapy market is include Novartis AG, Amgen, Celgene Corporation, Pfizer Inc., Fate Therapeutics, Bluebird Bio Inc., TCR2 Therapeutics Inc, Sorrento Therapeutics, Gilead Sciences Inc., Merck KGaA, etc.The competitive environment of the T-cell therapy market is anticipated to be impacted by the increasing number of businesses engaged in the development of CAR-T treatments. The market for T-cell treatment is now controlled by Novartis AG thanks to new product development and developments.
Market Taxonomy
By Modality
By Therapy Type
By Indication
By End User
By Region
- 1 Introduction
- 1.1 Objective of the Study
- 1.2 Market definition
- 1.3 Market Scope
- 2 Research Methodology
- 2.1 Data Mining
- 2.2 Validation
- 2.3 Primary Interviews
- 2.4 List of Data Sources
- 3 Executive Summary
- 4 Global T-Cell Therapy Market Outlook
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
- 5 Global T-Cell Therapy Market, By Modality
- 5.1 Y-o-Y Growth Comparison, By Modality
- 5.2 Global T-Cell Therapy Market Share Analysis, By Modality
- 5.3 Global T-Cell Therapy Market Size and Forecast, By Modality
- 5.3.1 Research
- 5.3.2 Commercialized
- 6 Global T-Cell Therapy Market, By Therapy Type
- 6.1 Y-o-Y Growth Comparison, By Therapy Type
- 6.2 Global T-Cell Therapy Market Share Analysis, By Therapy Type
- 6.3 Global T-Cell Therapy Market Size and Forecast, By Therapy Type
- 6.3.1 CAR T-cell Therapy
- 6.3.2 T Cell Receptor (TCR)-based
- 6.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
- 7 Global T-Cell Therapy Market, By Indication
- 7.1 Y-o-Y Growth Comparison, By Indication
- 7.2 Global T-Cell Therapy Market Share Analysis, By Indication
- 7.3 Global T-Cell Therapy Market Size and Forecast, By Indication
- 7.3.1 Hematologic Malignancies
- 7.3.2 Solid Tumors
- 7.3.3 Others
- 8 Global T-Cell Therapy Market, By End User
- 8.1 Y-o-Y Growth Comparison, By End User
- 8.2 Global T-Cell Therapy Market Share Analysis, By End User
- 8.3 Global T-Cell Therapy Market Size and Forecast, By End User
- 8.3.1 Hospitals
- 8.3.2 Clinics & Ambulatory Centers
- 8.3.3 Cancer Research Institutes
- 8.3.4 Others
- 9Global T-Cell Therapy Market, By Region
- 9.1 Global T-Cell Therapy Market Share Analysis, By Region
- 9.2 Global T-Cell Therapy Market Share Analysis, By Region
- 9.3 Global T-Cell Therapy Market Size and Forecast, By Region
- 10 North America T-Cell Therapy Analysis and Forecast (2022-2027)
- 10.1 Introduction
- 10.2 North America T-Cell Therapy Product Market Share Analysis, By Modality
- 10.3 North America T-Cell Therapy Product Market Size and Forecast, By Therapy Type
- 10.4 North America T-Cell Therapy Product Market Size and Forecast, By Indication
- 10.5 North America T-Cell Therapy Product Market Size and Forecast, By End User
- 10.6 North America T-Cell Therapy Product Market Size and Forecast, By Country
- 10.6.1 U.S.
- 10.6.2 Canada
- 10.6.3 Mexico
- 11Europe T-Cell Therapy Market Analysis and Forecast (2022-2027)
- 11.1 Introduction
- 11.2 Europe T-Cell Therapy Product Market Share Analysis, By Modality
- 11.3 Europe T-Cell Therapy Product Market Size and Forecast, By Therapy Type
- 11.4 Europe T-Cell Therapy Product Market Size and Forecast, By Indication
- 11.5 Europe T-Cell Therapy Product Market Size and Forecast, By End User
- 11.6 Europe T-Cell Therapy Product Market Size and Forecast, By Country
- 11.6.1 Germany
- 11.6.2 France
- 11.6.3 UK
- 11.64. Rest of Europe
- 12Asia Pacific T-Cell Therapy Market Analysis and Forecast (2022-2027)
- 12.1 Introduction
- 12.2 Asia Pacific T-Cell Therapy Product Market Share Analysis, By Modality
- 12.3 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Therapy Type
- 12.4 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Indication
- 12.5 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By End User
- 12.6 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Country
- 12.6.1 China
- 12.6.2 Japan
- 12.6.3 India
- 12.6.4. Rest of Asia Pacific
- 13Latin America T-Cell Therapy Market Analysis and Forecast (2022-2027)
- 13.1 Introduction
- 13.2 Latin America T-Cell Therapy Product Market Share Analysis, By Modality
- 13.3 Latin America T-Cell Therapy Product Market Size and Forecast, By Therapy Type
- 13.4 Latin America T-Cell Therapy Product Market Size and Forecast, By Indication
- 13.5 Latin America T-Cell Therapy Product Market Size and Forecast, By End User
- 13.6 Latin America T-Cell Therapy Product Market Size and Forecast, By Country
- 14Middle East T-Cell Therapy Market Analysis and Forecast (2022-2027)
- 14.1 Introduction
- 14.2 Middle East T-Cell Therapy Product Market Share Analysis, By Modality
- 14.3 Middle East T-Cell Therapy Product Market Size and Forecast, By Therapy Type
- 14.4 Middle East T-Cell Therapy Product Market Size and Forecast, By Indication
- 14.5 Middle East T-Cell Therapy Product Market Size and Forecast, By End User
- 14.6 Middle East T-Cell Therapy Product Market Size and Forecast, By Country
- 15Competitive Analysis
- 15.1 Competition Dashboard
- 15.2 Market share Analysis of Top Vendors
- 15.3 Key Development Strategies
- 16Company Profiles
- 16.1 Novartis AG
- 16.1.1 Overview
- 16.1.2 Offerings
- 16.1.3 Key Financials
- 16.1.4 Business Segment & Geographic Overview
- 16.1.5 Key Market Developments
- 16.1.6 Key Strategies
- 16.2 Amgen
- 16.2.1 Overview
- 16.2.2 Offerings
- 16.2.3 Key Financials
- 16.2.4 Business Segment & Geographic Overview
- 16.2.5 Key Market Developments
- 16.2.6 Key Strategies
- 16.3 Celgene Corporation
- 16.3.1 Overview
- 16.3.2 Offerings
- 16.3.3 Key Financials
- 16.3.4 Business Segment & Geographic Overview
- 16.3.5 Key Market Developments
- 16.3.6 Key Strategies
- 16.4 Pfizer Inc
- 16.4.1 Overview
- 16.4.2 Offerings
- 16.4.3 Key Financials
- 16.4.4 Business Segment & Geographic Overview
- 16.4.5 Key Market Developments
- 16.4.6 Key Strategies
- 16.5 Fate Therapeutics
- 16.5.1 Overview
- 16.5.2 Offerings
- 16.5.3 Key Financials
- 16.5.4 Business Segment & Geographic Overview
- 16.5.5 Key Market Developments
- 16.5.6 Key Strategies
- 16.6 Bluebird Bio Inc
- 16.6.1 Overview
- 16.6.2 Offerings
- 16.6.3 Key Financials
- 16.6.4 Business Segment & Geographic Overview
- 16.6.5 Key Market Developments
- 16.6.6 Key Strategies
- 16.7 TCR2 Therapeutics Inc
- 16.7.1 Overview
- 16.7.2 Offerings
- 16.7.3 Key Financials
- 16.7.4 Business Segment & Geographic Overview
- 16.7.5 Key Market Developments
- 16.7.6 Key Strategies
- 16.8 Sorrento Therapeutics
- 16.8.1 Overview
- 16.8.2 Offerings
- 16.8.3 Key Financials
- 16.8.4 Business Segment & Geographic Overview
- 16.8.5 Key Market Developments
- 16.8.6 Key Strategies
- 16.9 Gilead Sciences Inc
- 16.9.1 Overview
- 16.9.2 Offerings
- 16.9.3 Key Financials
- 16.9.4 Business Segment & Geographic Overview
- 16.9.5 Key Market Developments
- 16.9.6 Key Strategies
- 16.10 Merck KGaA
- 16.10.1 Overview
- 16.10.2 Offerings
- 16.10.3 Key Financials
- 16.10.4 Business Segment & Geographic Overview
- 16.10.5 Key Market Developments
- 16.10.6 Key Strategies
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook